Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Accumulated Expenses data on file, last reported at $60.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $60.0 million, up 35.14% year-over-year; the trailing twelve-month figure through Feb 2026 was $60.0 million (up 35.14% YoY), and the FY2025 annual result was $54.9 million, up 44.37% from the prior year.
• Accumulated Expenses grew to $60.0 million in Q1 2026 per NRIX's latest filing, from $54.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $60.0 million in Q1 2026 and troughed at $4.0 million in Q1 2022.
• A 5-year average of $28.4 million and a median of $25.0 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses tumbled 44.89% in 2022, then soared 284.32% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $22.4 million in 2022, then climbed by 11.33% to $25.0 million in 2023, then surged by 52.16% to $38.0 million in 2024, then soared by 44.37% to $54.9 million in 2025, then gained by 9.29% to $60.0 million in 2026.
• Business Quant data shows NRIX's Accumulated Expenses at $60.0 million in Q1 2026, $54.9 million in Q4 2025, and $44.0 million in Q3 2025.